CTRI/2020/09/027790
Not yet recruiting
未知
Evaluation of Contraceptive Efficacy, Changes in Uterine Artery and Endometrial thickness in women using LNG IUS - CUELNG
Pregna International Limited0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Pregna International Limited
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Parous and nulliparous women choosing LNG IUS for interval contraception after Cafetaria method with GATHER approach,
- •2\. Willing to participate in the study
Exclusion Criteria
- •1 .Known or suspected Pregnancy
- •2\. Current Pelvic infection
- •3\. Uterine bleeding of unknown etiology,
- •4\. Post renal transplant patients
- •5\. Acute liver disease or liver tumor (benign or malignant)
- •6\. Known or suspected uterine or cervical neoplasia
- •7\. Chorio\-carcinoma patients on follow\-up
- •8\. Subjects at increased risk for infectious endocarditis (prosthetic heart valves, rheumatic heart disease, previous endocarditis)
- •9\. Women with a prior Tubectomy/trans cervical tubal sterilization procedure (e.g., Essure)
- •10\. Postmenopausal woman
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 3
A 12 week prospective study of efficacy and acceptability of magnesium sulfate once weekly in adults as a management regime for constipation.ConstipationOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12609000081213Colocap Pharmaceuticals Pty Ltd100
Active, not recruiting
Not Applicable
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder.A 8 to 10 weeks open period treatment with agomelatine (25 mg to 50 mg) followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.Major Depressive DisorderMedDRA version: 3.3Level: P.T.Classification code 10025453EUCTR2004-003981-13-FIInstitut de Recherches Internationales Servier500
Active, not recruiting
Phase 1
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelatine (25 mg to 50 mg) followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.Major Depressive DisorderMedDRA version: 3.3 Level: P.T. Classification code 10025453EUCTR2004-003981-13-GBInstitut de Recherches Internationales Servier500
Completed
Not Applicable
Efficacy test for evaluating the effect of "composition A" on the skin redness.Healthy peopleJPRN-UMIN000029583Kao Corporation25
Completed
Not Applicable
A confirmation study for the improvement effect of skin quality by the test food consumptioot applicableJPRN-UMIN000037734CPCC Company Limited110